Clinical trial

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

NCT06339658

Study summary

ClinicalTrials.gov

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

Design: OBSERVATIONAL · Status: RECRUITING · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

PROCEDURE · Unmapped registry intervention Targeted axillary dissection (TAD) by ICG Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Targeted axillary dissection (TAD) by Blue patent Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2021-01-01

PhaseN/A

Conditions

Breast Cancerverified · MONDO: breast cancer

Axillary Metastasesunresolved

Interventions

Targeted axillary dissection (TAD) by ICGPROCEDURE

Targeted axillary dissection (TAD) by Blue patentPROCEDURE

Sponsors & collaborators

Hospital Universitari de Bellvitgelead sponsor

Mapped research locations

L'Hospitalet de LlobregatBarcelona, Spain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06339658 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.